All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Is fedratinib a safe and efficacious treatment option for patients with PMF and low platelet counts?

Jan 20, 2020
Share:

The MPN Hub were pleased to speak to Ruben Mesa, University of Texas Health Science Center, San Antonio, US, during the 61st American Society of Hematology Meeting & Exposition in Orlando, US. We asked: Is fedratinib a safe and efficacious treatment option for patients with primary myelofibrosis and low platelet counts?

Ruben Mesa discusses two major studies that assessed fedratinib (JAK2 inhibitor) in patients with primary myelofibrosis; the randomized phase III trial JAKARTA study and the JAKARTA2 second-line study. He discusses the safety and efficacy of both trials.

Is fedratinib a safe and efficacious treatment option for patients with PMF and low platelet counts?